Syncom Formulations is trading at ₹20.90, down 5.34%, with no clear reason identified for the decline.
- No company-specific announcement explaining the October 23, 2026 decline surfaced in the search.
- The latest identified filing was routine regulatory compliance; AGM and dividend news predated the move.
- The supplied healthcare-sector context was positive, and no verified same-direction market catalyst or direct cause was identified.